 SAN DIEGO, Sept. 09, 2022 GLOBE NEWSWIRE -- Erasca, Inc. Nasdaq: ERAS, a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RASMAPK pathway-driven cancers, today announced its participation in the Morgan Stanley Global Healthcare Conference. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer, will represent Erasca in a fireside chat at 12:55 pm Eastern Time on Wednesday, September 14, 2022, at the Sheraton Hotel in New York, New York. Drs. Lim and Chacko will also participate in one-on-one investor meetings. 